Illumina gets a $40M commitment to back genomic startups; Biota bags Anaconda and lead antiviral in buyout;

@FierceBiotech: After painful odyssey, Newron wins European OK for Parkinson's add-on. News | Follow @FierceBiotech

@JohnCFierce: Top story of the week: Exclusive: Pfizer is once again cutting back R&D staff in reorganization. Report | Follow @JohnCFierce

@DamianFierce: Hey so @FierceBiotech has a podcast now, and you can listen online and subscribe on iTunes. | Follow @DamianFierce

> San Francisco-based Illumina ($ILMN) reports that it has gained a $40 million commitment from Viking Global Investors to seed promising genomic startups that come out of its incubator. Release

> Atlanta-based Biota ($BOTA) has acquired Paris-based Anaconda Pharma and its lead antiviral for $8 million in cash, 3.5 million shares and up to $30 million in milestones. Anaconda Pharma's lead candidate is AP611074, an antiviral in development for condyloma, or anogenital warts, as well as the orphan disease recurrent respiratory papillomatosis. Release

> Amarin ($AMRN) is getting $15 million upfront and up to $154 million in milestones from Eddingpharm in exchange for development and commercialization rights to Vascepa in China. Release

Medical Device News

@FierceMedDev: ICYMI yesterday: In a medical first, three patients receive prosthetic hands in place of disabled ones. Article | Follow @FierceMedDev

@VarunSaxena2: Roche, BioMed X to jointly run diagnostics incubator in Germany. FierceDiagnostics story | Follow @VarunSaxena2

@EmilyWFierce: Cyberonics and Sorin to form U.K.-based company valued at $2.7B, aiming to boost hospital offerings. More from Bloomberg | Follow @EmilyWFierce

> Indian diagnostics company Thyrocare aims for $100M IPO. News

> FDA warns manufacturer of failing to report corrections to its device disinfection system. Report

Pharma News

@FiercePharma: Deal-weighing Pharmacyclics could draw $18B from J&J, Novartis: Bloomberg. Report | Follow @FiercePharma

@CarlyHFierce: ICYMI yesterday: Sidelined after tampering incident, GSK's alli is back on sale. Report | Follow @CarlyHFierce

> SC's top court backs Risperdal verdict against J&J, but cuts penalty to $136M. Story

> Sanofi's fight for Toujeo market share won't be easy, analysts say. Article

Vaccines News

> NewLink nets $20M Ebola milestone from Merck. Item

> Valeant touts PhII Provenge data following Dendreon buy. More

> Takeda places vaccines unit in Singapore to push for global growth. Article

> Combo of Bavarian Nordic's Prostvac and BMS' Yervoy yields promising PhI results. Story

> Pfizer trumpets positive Trumenba data ahead of ACIP vote. Report

Pharma Manufacturing News

> Impax reports significant jump in revenues as it gets plant problems behind it. Report

> Unused Forest Labs facility snapped up by Aprecia Pharmaceuticals. News

> New Jersey compounder indicted over unsanitary manufacturing. Story

> Bharat, Serum Institute ramp up production of their swine flu vaccines. Item

> Federal judge cuts off Maine's Internet drug supply chain. Article

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.